Xponance, Inc. Lineage Cell Therapeutics, Inc. Transaction History
Xponance, Inc.
- $10.7 Billion
- Q4 2024
A detailed history of Xponance, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 10,456 shares of LCTX stock, worth $5,123. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,456Holding current value
$5,123% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$20.4 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.68 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$4.23 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$3.55 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$2.92 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $83.2M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...